ADJUNCT ONE was a 52-week, double-blind, treat-to-target study conducted in 1398 people randomised 3:1 to receive liraglutide (1.8 mg, 1.2 mg or 0.6 mg) or placebo, in 177 centres in 17 countries (Mathieu et al, 2016)
Data availability No datasets were generated or analysed during the current study
Quick Tips Complement the supplement with a balanced diet rich in fruits, vegetables, and antioxidants to support overall skin health and enhance the supplements effects
Billions of injections occur across the United States healthcare systems
Unlocks access to GLP-1s, licensed providers, and ongoing care
Activates MC1R (melanogenesis), MC3/4R (appetite + libido), and MC5R (sebaceous gland)